X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
Lead Product(s): Atezolizumab,Immunoglobulin G2,Immunoglobulin G4
Therapeutic Area: Infections and Infectious Diseases Product Name: HGM
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 07, 2021
Details:
maintained the native binding properties of rituximab, with data demonstrating KPMW135’s ability to bind CD16a/FcgRIIIA and FcRn via the Fc domain, as well as CD20 binding on target tumor cells via the Fab domains.
Lead Product(s): KPMW135
Therapeutic Area: Oncology Product Name: KPMW135
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
KP1237 is an antibody-redirecting molecule (ARMä) that targets CD38, a clinically validated target for multiple myeloma.
Lead Product(s): KP1237,NK Cell Therapy
Therapeutic Area: Oncology Product Name: KP1237
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
The research collaboration aims to rapidly advance synergistic combinations of each company’s technology platform as potential treatments for COVID-19 and multiple myeloma.
Lead Product(s): NK cell therapy,Antibody recruiting molecule
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Celularity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 21, 2020
Details:
Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT.
Lead Product(s): KP1237,NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Kleo's first non-oncology application of its antibody recruiting molecule (ARM™) to be tested in combination with GCLC'S NK cells as a potential COVID-19 therapeutic.
Lead Product(s): NK cell therapy,Antibody recruiting molecule
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Green Cross Lab Cell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 31, 2020
Details:
KP1237, a CD38-Targeting antibody recruiting molecule (ARM™), to be tested in combination with NK Cells to treat post-transplant multiple myeloma patients.
Lead Product(s): KP1237,NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
